Quality of life predicts rehabilitation prognosis in Parkinson’s disease patients

Factors influence rehabilitation prognosis

Detao Meng1 | Zhaohui Jin1 | Keke Chen2 | Xin Yu2 | Yixuan Wang1 | Wenjun Du1 | Jingran Wei1 | Jianing Xi1 | Boyan Fang1

1Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China
2Beijing Rehabilitation Medical College, Capital Medical University, Beijing, China

Correspondence
Boyan Fang and Jianing Xi, Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University, Badachu, Xixiazhuang, Shijingshan District, Beijing 100144, China. Email: fangboyan@ccmu.edu.cn; xijn888@sina.com

Detao Meng and Zhaohui Jin contributed equally to this work.

Funding information
National Key R&D Program of China, Grant/Award Number: 2018YFC0115405; Science and Technology Development Fund of Beijing Rehabilitation Hospital, Capital Medical University, Grant/Award Numbers: 2019R-006, 2020-069, 2020-067

Abstract
Background: Rehabilitation has been reported to improve the quality of life (QoL) of patients with Parkinson’s disease (PD). Nevertheless, not all patients are satisfied with rehabilitation outcomes and could achieve a significant improvement in QoL.

Objective: To detect possible predictors of QoL improvement in patients with PD after rehabilitation.

Methods: A total of 86 PD patients were included and followed up for 3 months with a 39-item Parkinson’s Disease Questionnaire summary index (PDQ-39 SI) as the primary endpoint. All patients received 2 weeks of multidisciplinary intensive rehabilitation treatment (MIRT). Changes in patients’ QoL were assessed using the PDQ-39 at baseline and at the 3-month follow-up. The reliable change index (RCI) was adapted to determine the individual QoL outcome. The predictors of QoL outcome were detected using logistic regression analysis.

Results: After a 3-month follow-up, PDQ-39 SI decreased significantly from 22.95 ± 9.75 to 18.73 ± 10.32 (P < 0.001). Scores for QoL improved (RCI > 10.9) after rehabilitation for 18.6% of the patients, and 74.4% of patients reported an unchanged QoL (−10.9 ≤ RCI ≤ 10.9), while 7.0% of patients reported a worsening of QoL (RCI < −10.9).

Among the baseline parameters, the PDQ-39 SI was a baseline predictor for changes in QoL in the logistic regression model (OR: 1.15, CI: 1.07–1.24, P < 0.001).

Conclusions: MIRT could improve QoL for some patients with PD, and PDQ-39 score at baseline is the most important predictor for QoL improvements after rehabilitation for this patients.

KEYWORDS
health-related quality of life, Parkinson’s disease, PDQ-39, predictor, rehabilitation

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
1 | INTRODUCTION

Parkinson’s disease (PD) is a progressive neurodegenerative disease that is characterized by motor symptoms such as bradykinesia, resting tremor, rigidity, and a sequence of nonmotor symptoms, such as cognitive decline, anxiety, and depression (Bloem et al., 2021). It can lead to a decline in quality of life (QoL) very early and deteriorates as the disease progresses (Carod-Artal et al., 2007), even under the best medical treatment or with deep brain stimulation (Daniels et al., 2011). Therefore, rehabilitation therapies are considered an adjutant to pharmacological and surgical treatments to maximize functional abilities and to minimize secondary complications (Armstrong & Okun, 2020).

Meanwhile, rehabilitation has also been reported to improve the QoL related to PD (Clarke et al., 2016; Ferrazzoli et al., 2018; Monticone et al., 2015; Morris et al., 2009; Rodrigues De Paula et al., 2006; Tickle-Degnen et al., 2010), but not all studies yield the same results (Wade et al., 2003). Although several reasons could explain the lack of benefit, such as previously satisfactory management leaving little room for improvement, lack of psychological intervention, etc. (Playford, 2003).

Therefore, this revealed that not all patients are satisfied with the rehabilitation results and can achieve a significant improvement in QoL. The reasons may be multidimensional, but strategies to identify which patient could benefit from rehabilitation seem to be important for optimized treatment outcomes. For instance, we can adopt different rehabilitation strategies for patients with different outcomes to reduce the waste of medical resources and improve the therapeutic effect of individual patients. On the other hand, for those who may benefit less, other treatment methods should be actively adopted to improve the patient’s QoL as much as possible.

Therefore, we performed this study to understand the effects of multidisciplinary intensive rehabilitation treatment (MIRT) for mild to moderate PD patients. In particular, the relative contributions of motor and nonmotor baseline parameters to the rehabilitation outcome on QoL were analyzed. We attempted to detect the possible predictors of QoL improvement for PD patients after rehabilitation with a 3-month follow-up.

2 | METHODS

2.1 | Study population

In this ongoing, prospective single-center cohort study (multidisciplinary rehabilitation registration study on PD, registration number: ChiCTR2000033768), a total of 86 PD patients attending our inpatient rehabilitation project in Beijing Rehabilitation Hospital from June 2020 to July 2021 were included and followed up for 3 months. All patients received 2 weeks of MIRT. None of the patients underwent drug adjustment from training to 3 months of follow-up. Inclusion criteria were: (1) idiopathic PD as confirmed by a neurologist using the Movement Disorder Society criteria (Postuma et al., 2015); (2) no deep brain stimulation or in vivo implantation treatment; (3) were able to understand each item of the informed consent and willing to sign the informed consent.

The exclusion criteria were as follows: (1) atypical parkinsonism, such as multiple system atrophy, corticobasal degeneration, and progressive supranuclear palsy; (2) serious medical conditions, such as severe coronary heart disease, backache, and malignancy; and (3) individuals with dementia or severe psychiatric symptoms. (4) Hoehn & Yahr (H&Y) Stage: 4–5; (5) patients with frequent falls; (6) age > 80.

This research was approved by the ethics committee of the Beijing Rehabilitation Hospital (2020bkky010). All participants signed informed consent following the Declaration of Helsinki. Clinical and demographic data at baseline collected included sex, age, age at diagnosis, disease duration, levodopa equivalent daily dose (LEDD), H&Y stage (Hoehn & Yahr, 1967), and MDS-UPDRS score (Goetz et al., 2007). The evaluation of the H&Y stage and MDS-UPDRS score were carried out under the medication ON stage.

2.1.1 | MIRT procedure

MIRT is specifically designed for rehabilitation for PD patients and is constituted with a multidisciplinary, aerobic, motor-cognitive, intensive, and goal-based rehabilitation treatment (Ferrazzoli et al., 2018; Frazzitta et al., 2012; Frazzitta et al., 2015). All patients received a 2 weeks of MIRT. The 2-week program comprised four sessions. The first session is one-on-one physical therapy by a physical therapist for 30 min. The second session is a 60-min goal-directed balance and gait training combined with motor-cognitive dual tasks by an augmented reality treadmill (C-MILL, Motek, Amsterdam/Culemborg, Netherlands) and Balance Tutor (Meditouch, Netanya, Israel). The third session is a 30-min aerobic training on an upper and lower limb trainer (T5XR; Nustep, Ann Arbor, MI, USA) and the fourth session is 30-min speech therapy. All the training was conducted in a hospital setting, 5 days per week, and the details were described elsewhere (Chen et al., 2021).

2.2 | Clinical assessments

QoL was assessed by the Chinese version of the Parkinson’s Disease Questionnaire (PDQ-39) (Neff et al., 2018). The PDQ-39 is a validated disease-specific HRQoL measure in PD (Neff et al., 2018) that contains eight domains: mobility, activities of daily life, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 summary index (PDQ-39 SI) was calculated to measure overall health-related QoL, and a higher score (range 0–100) indicates a more severe burden of QoL. The outcome parameters were the PDQ-39 SI. The differences between the follow-up 3 months after rehabilitation and baseline scores were calculated as outcome parameters. The Reliable Change Index (RCI) was adapted to determine the individual outcome of QoL after rehabilitation (Daniels et al., 2011; Jacobson & Truax, 1991). A PDQ-39 score decrease of more than 10.9 points was termed “improved,” and a score increase of more than 10.9 points was termed “worsen”; changes between –10.9 and 10.9 were termed “unchanged” (Daniels et al., 2011; Floden et al., 2014; Liu et al., 2014).
Both the “worsen” and “unchanged” groups were assigned to the “nonimproved” group.

Furthermore, cognitive function was evaluated by the Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005), depression was evaluated by the Geriatric Depression Scale (GDS) (Montorio & Izal, 1996), fatigue was evaluated by the Parkinson Fatigue Scale (PFS-16) (Brown et al., 2005), and apathy was evaluated by the Modified Apathy Evaluation Scale (MAES) (Starkstein et al., 1992) at baseline as a factor that affects QoL according to the literature (D’Iorio et al., 2017; Rahman et al., 2008; Rahman et al., 2008; Tang et al., 2020).

2.3 Statistical analysis

Data distribution and normality were evaluated with the Shapiro–Wilk test. Normally distributed data are expressed as the mean ± standard deviation (SD), while nonnormally distributed data are reported as the median (interquartile range). The PDQ-39 SI and subgroup score at baseline and with follow-up for 3 months were compared by the paired sample t test. Spearman correlations or Pearson correlations were used to explore the relationship between changes in QoL scores and demographic and clinical parameters, including age, age at diagnosis, disease duration, LEDD, H&Y stage, MDS-UPDRS score, GDS, MAES, PFS-16, and PDQ-39 SI score at baseline. Spearman’s correlation was also used to evaluate changed nonmotor parameters, including GDS, MAES, and PFS-16 scores, associated with changes in QoL.

Furthermore, demographic and clinical parameters at baseline were compared between the “improved” and “nonimproved” groups according to the PDQ-39 RCI using univariate analysis. Demographic and clinical parameters at baseline as revealed by the first-step analyses (less strictly selected: P < 0.10, one-tailed) were included in a logistic regression analysis as independent variables with the dichotomous variable improved/nonimproved in terms of the PDQ-39 RCI as the dependent variable. P values < 0.05 (two-tailed) were regarded as significant. Receiver operating characteristic (ROC) analyses were used to evaluate the predictive utility of logistic regression models on patients’ QoL improvement (Schrag et al., 2017). These statistical data were analyzed using SPSS version 21 (SPSS Inc., Chicago, IL).

3 RESULTS

Of 155 patients screened, 86 patients (36 males) were included in the final analysis (see Figure 1). The mean age at baseline was 60.24 years (SD = 7.82), and the median disease duration was 6.00 years (interquartile range = 4.00). The patient baseline characteristics are shown in Table 1.

3.1 The effects of MIRT for mild to moderate PD patients

After a 3-month follow-up, scores for QoL improved (RCI > 10.9) after rehabilitation for 18.6% of the patients (16 of 86 patients) and were assigned to the “improved” group. 74.4% of patients (64 of 86 patients) reported an unchanged QoL (−10.9 ≤ RCI ≤ 10.9), and 7.0% of patients (6 of 86 patients) reported a worsening of QoL (RCI < −10.9). Both of them were assigned to the “nonimproved” group. The PDQ-39 SI at baseline was 22.95 ± 9.75, and it decreased significantly to 18.73 ± 10.32 (P < 0.001) with a 3-month follow-up. The overall effects of MIRT for mild to moderate PD patients are shown in Figure 2.

In the PDQ-39 subgroup, the cognition (from 29.87 ± 16.95 to 25.87 ± 15.01, P = 0.008), stigma (from 27.03 ± 25.77 to 19.55 ± 17.59, P < 0.001), emotional wellbeing (from 24.90 ± 18.13 to 21.07 ± 18.39, P = 0.001), and sexual function (from 14.69 ± 13.24 to 11.06 ± 12.90, P = 0.001) were significantly improved.

Excluded(39)
1. Atypical Parkinson(5)
2. H&Y stage: 4-5(5)
3. Serious medical conditions(17)
4. Dementia or severe psychiatric disorders(4)
5. Age ≥ 80 (6)
6. Patients with frequent falls(2)

Excluded(30)
1. Withdrew consent(8)
2. Hospitalization is not possible due to COVID-19(19)
3. DBS will perform recently(2)
4. Loss to follow-up(1)

FIGURE 1 Participants flow chart. The flow chart describes the enrollment of patients.
TABLE 1  Patient characteristics at baseline

|                          | Baseline              |
|--------------------------|-----------------------|
| Male^a, n (%)            | 36 (41.86%)           |
| Age at onset^b (y)       | 54.00 (9.00)          |
| Age^c (y)                | 60.24 ± 7.82          |
| Disease duration^b (y)   | 6.00 (4.00)           |
| LEDD^b (mg/d)            | 520.50 (362.50)       |
| Jankovic subtypes^a, n (%) |                     |
| Tremor dominant          | 31 (36.1%)            |
| Postural instability/gait dominant | 48 (55.8%) |
| Indeterminate            | 7 (8.1%)              |
| Hoehn and Yahr Stage^b   | 2.00 (0.50)           |
| UPDRS part I score^c     | 8.00 (5.50)           |
| UPDRS part II score^c    | 11.81 ± 6.21          |
| UPDRS part III score^c   | 32.62 ± 13.73         |
| UPDRS part IV score^c    | 2.00 (5.00)           |
| MoCA^c                   | 25.20 ± 4.37          |
| GDS^b                    | 8.00 (10.00)          |
| MAES^b                   | 11.00 (15.00)         |
| PFS-16^c                 | 42.45 ± 13.88         |
| PDQ-39 SI^c              | 22.95 ± 9.75          |

GDS, Geriatric Depression Scale; LEDD, levodopa equivalent daily dose; MAES, Modified Apathy Evaluation Scale; MoCA, Montreal Cognitive Assessment; PDQ-39 SI, Parkinson’s Disease Questionnaire-39 summary index; PFS-16, Parkinson Fatigue Scale; UPDRS, Unified Parkinson’s Disease Rating Scale.

^a Count data are expressed as n (%).

^b Non-normal data are reported as the median (interquartile range).

^c Normally distributed data are expressed as the mean ± SD.

± 14.98, P = 0.035), and mobility (from 28.87 ± 16.17 to 18.69 ± 17.07, P < 0.001) domains decreased significantly; however, the communication domain increased significantly from 7.36 ± 12.29 to 14.63 ± 15.01 (P < 0.001). Bodily discomfort, social support, and activities of daily living showed no significant changes. In the “improved” group, the bodily discomfort (P = 0.029), cognition (P = 0.002), emotional wellbeing (P < 0.001), activity of daily living (P = 0.002), and mobility (P < 0.001) domains decreased significantly. There is a downward trend in the social support and communication domain. In the “nonimproved” group, the mobility domain decreased significantly (P < 0.001); however, there was no significant change or increase in other domains. The PDQ-39 subgroup analysis was shown in Figure 3.

3.2 | Correlation analyses

PDQ-39 SI at baseline was significantly associated with changes in the PDQ-39 SI after a 3-month follow-up (r = 0.422, P < 0.001). Meanwhile, the changes in the PDQ-39 SI were significantly associated with GDS score changes (r = 0.537, P < 0.001) and MAES score changes (r = 0.284, P < 0.01) after a 3-month follow-up. The correlation analysis results are shown in Appendix 1.

3.3 | Logistic regression analysis

Table 2 includes unadjusted ORs for bivariable analyses and adjusted ORs for multivariate analyses assessing the magnitude of association between each candidate predictor and the outcome. GDS (P = 0.013) and PDQ-39 SI (P < 0.001) at baseline showed significant relationships with the outcome. For every additional GDS score, patients displayed a 12.5% higher odds of improvement in QoL (OR = 1.125, 95% confidence interval [CI] 1.025–1.235, P = 0.013). For every additional score of the PDQ-39, patients displayed a 15.1% higher odds of improvement in QoL (OR = 1.151, 95% CI 1.067–1.241, P < 0.001). The multivariate regression model included three factors at baseline with P < 0.1 in the univariate analysis: PDQ-39 SI (P < 0.001), GDS (P = 0.013), and age (P = 0.098). Only the PDQ-39 SI remained significant (P < 0.001) as a baseline predictor for change in QoL in the multivariate model with the likelihood ratio method. The PDQ-39 SI at baseline was included in the final model. In the final model, for every additional score of the PDQ-39, patients displayed a 15.1% higher odds of improvement in QoL.

FIGURE 2  The effects of MIRT for mild to moderate PD patients. Left: For the PDQ-39 SI, improved, unchanged, and worsened groups are shown in the percent of cases. QoL improved in 18.6% of patients, 74.4% of patients had no changes in QoL, QoL deteriorated in 7.0% of patients. Right: The PDQ-39 SI at baseline decreased significantly from baseline to the 3-month follow-up. (PDQ-39 SI: PD Questionnaire-39 summary score, *P < 0.05). MIRT, multi-disciplinary intensive rehabilitation treatment.
FIGURE 3  The effects of MIRT for mild to moderate PD patients in the PDQ-39 subgroup. The comparison of PDQ-39 subgroup scores for all patients, the unimproved group, and the improved group at baseline and after rehabilitation is separately shown on the left of the dotted line, between the two dotted lines, and on the right of the dotted line. The cognition, stigma, emotional wellbeing, and mobility domains decreased significantly, and the communication domain increased significantly. In the "improved" group, bodily discomfort, cognition, stigma, emotional wellbeing, activities of daily living, and mobility domains decreased significantly. In the "nonimproved" group, the mobility domain decreased significantly, and there was no change or increase significantly in other domains (T, total; NI, nonimproved; I, improved. *P < 0.05, **P < 0.01, ***P < 0.001). MIRT, multi-disciplinary intensive rehabilitation treatment

TABLE 2  Univariate and multivariate analysis of predictors of PDQ-39 after 3 months

| Variables                          | Univariate analysis | Multivariate analysis |
|------------------------------------|---------------------|-----------------------|
|                                    | OR (95% CI)         | P value               | OR (95% CI)         | P value               |
| Male/female                        | 2.048(0.682–6.144)  | 0.201                 |                      |                       |
| Age at onset (y)                   | 1.037(0.965–1.114)  | 0.320                 |                      |                       |
| Age (y)                            | 1.070(0.987–1.160)  | 0.098                 |                      |                       |
| Disease duration (y)               | 1.058(0.948–1.180)  | 0.317                 |                      |                       |
| LEDD(mg/d)                         | 1.000(0.999–1.002)  | 0.619                 |                      |                       |
| Jankovic subtype, n (%)            |                     |                       |                      |                       |
| Tremor dominant                    | 1                   |                       |                      |                       |
| Postural instability/gait dominant | 1.750(0.179–17.080) | 0.630                 |                      |                       |
| Indeterminate                      | 1.200(0.127–11.374) | 0.874                 |                      |                       |
| Hoehn and Yahr Stage               | 0.829(0.265–2.592)  | 0.747                 |                      |                       |
| UPDRS part I score                 | 1.052(0.950–1.165)  | 0.327                 |                      |                       |
| UPDRS part II score                | 1.004(0.919–1.096)  | 0.929                 |                      |                       |
| UPDRS part III score               | 0.980(0.941–1.022)  | 0.344                 |                      |                       |
| UPDRS part IV score                | 0.941(0.771–1.148)  | 0.547                 |                      |                       |
| MoCA                               | 1.043(0.899–1.211)  | 0.576                 |                      |                       |
| MAES                               | 1.046(0.980–1.117)  | 0.176                 |                      |                       |
| PFS-16                             | 1.013(0.974–1.054)  | 0.511                 |                      |                       |
| GDS                                | 1.125(1.025–1.235)  | 0.013                 |                      |                       |
| PDQ-39                             | 1.151(1.067–1.241)  | <0.001*               | 1.151(1.067–1.241)  | <0.001*               |

GDS, geriatric depression scale; LEDD, levodopa equivalent daily dose; MAES, Modified Apathy Evaluation Scale; MoCA, Montreal Cognitive Assessment; PDQ-39: Parkinson’s Disease Questionnaire-39; UPDRS, Unified Parkinson’s Disease Rating Scale; PFS-16, Parkinson Fatigue Scale.

*P < 0.05.
QoL (OR = 1.151, 95% CI 1.067-1.241, P < 0.001). The area under the ROC curve (AUC) for this model was 0.83 [0.726-0.935, P < 0.001]. The ROC curve for the model is displayed in Figure 4.

4 | DISCUSSION

Consistent with previous reports (Ferrazzoli et al., 2018; Monticone et al., 2015; Rafferty et al., 2017), our findings suggest that in mild to moderate PD, MIRT could improve QoL for some patients with PD. Although several studies have suggested that rehabilitation treatment, such as MIRT, could effectively improve QoL in patients with PD (Ferrazzoli et al., 2018; Monticone et al., 2015; Oguh et al., 2014), our study showed that the same is not true for all PD patients. QoL improved steadily in only a fraction of patients with a relatively conservative index to define the change in QoL after rehabilitation (Daniels et al., 2011). Therefore, we developed a model that could be used to predict improvement in QoL after rehabilitation in PD patients. We found that impaired QoL was the most important predictor of benefit in mild to moderate PD after rehabilitation in our prognostic model. Furthermore, we found that changes in the PDQ-39-SI were significantly associated with PDQ-39 SI at baseline and were significantly associated with GDS score changes and MAES score changes.

Evidence of the positive effects of rehabilitation treatments in PD is increasing (Clarke et al., 2016; Ferrazzoli et al., 2018; Monticone et al., 2015; Morris et al., 2009; Rodrigues De Paula et al., 2006). Ferrazzoli et al.’s study (Ferrazzoli et al., 2018) suggested that MIRT, which consisted of a multidisciplinary, aerobic, intensive, and motor-cognitive rehabilitation treatment, could improve QoL in patients with PD that could last for 3 months (Ferrazzoli et al., 2018). Monticone et al.’s study (Monticone et al., 2015) found that PD patients could obtain a benefit from multidisciplinary rehabilitative care for at least 1 year after the intervention. Multidisciplinary rehabilitative care could change the course of motor impairment, balance, activities of daily living, and QoL. Morris et al.’s study (Morris et al., 2009) suggested that inpatient rehabilitation produces short-term reductions in disability and improvements in QoL in people with PD for at least 3 months. As mentioned above (Ferrazzoli et al., 2018; Monticone et al., 2015; Morris et al., 2009), our finding also suggest that the improvement of QoL was considered to be significant by MIRT in mild to moderate PD patients. QoL scores significantly improved for 18.6% of the patients with a more conservative method (Daniels et al., 2011). Another study showed that QoL improved in only 7% of patients who received the best medical treatment with the same definition of improvement (Daniels et al., 2011). In our PDQ-39 subgroup analysis, we also found that regardless of whether QoL improves, there are significant improvements in the mobility domain. The patients in the “improved” group obtained varying degrees of improvement in all PDQ-39 subgroup scores. Therefore, our study demonstrated that rehabilitation therapy is an effective adjuvant to pharmacological and surgical treatments to improve QoL in PD patients (Abbruzzese et al., 2016).

Schuepbach et al.’s study showed that impaired QoL is the most important predictor of benefit in patients with PD after deep brain stimulation of the subthalamic nucleus (Schuepbach et al., 2019). Although the principles and mechanisms of DBS are different from those of rehabilitation (Abbruzzese et al., 2016; Ashkan et al., 2017), such advanced research is worthy of our study and emulation. In our study, we assembled a model that predict the improvement of QoL who attended our inpatient rehabilitation. We found that the PDQ-39-SI at baseline was a significant predictor of QoL improvement and a heavier burden of QoL at baseline correlated with a better QoL improvement, which is consistent with Ritter’s study (Ritter & Bonsaksen, 2019). Ritter’s study also found that patients who have lower levels of initial QoL benefit more from rehabilitation. Furthermore, our model’s accuracy was confirmed by ROC curves with an AUC = 0.83. Although these results need confirmation in further studies, the results still have a certain guiding value for the choice of therapeutic strategies for PD patients.

Why is impaired QoL the most important predictor of benefit in patients with PD after rehabilitation? In our research, a worse QoL at baseline predicted improvement of QoL in mild to moderate PD patients. One possible reason is some patients had already had a good QoL, lead to limited room left for the improvement. Although patients’ QoL has been improved, but they cannot reach the RCI index criterion. Another possible reason is that patients with poor QoL tend to have more severe motor and nonmotor symptoms, which are the determinants of QoL. Rehabilitation therapy could improve the motor and nonmotor symptoms of PD (Lamotte et al., 2015; Rafferty et al., 2017), and consistent with previous reports (Rafferty et al., 2017), patients with advanced PD could obtain more benefit than those with mild PD from rehabilitation therapy.

There are some limitations to this study that must be acknowledged. First, an important limitation of our findings is the selected patient population. We collected only mild to moderate PD patients, which might lead to selection bias. PD patients in the H&Y:4-5 stage could not complete MIRT due to their serious condition, and they may need to adopt other rehabilitation strategies, so we did not include those patients. Second, due to the COVID-19 outbreak, patients were unable to get...
to the hospital for a detailed kinematic evaluation, such as UPDRS-III score and UPDRS part IV score, at the 3-month follow-up, which could reflect the improvement of the patient’s motor function and motor complications (Goetz et al., 2007). Last, our follow-up time was only 3 months. Although there is evidence that PD patients can benefit from rehabilitation treatments, it is unclear how long the benefits could last (Abbruzzese et al., 2016). A long-term observation still is needed.

In conclusion, the present study shows that MIRT could improve the QoL of PD patients, especially mild to moderate PD patients with impaired QoL. Impaired QoL at baseline could predict the benefit of rehabilitation for PD patients. Patients with impaired QoL should actively participate in rehabilitation exercises to improve their QoL. Further research is needed in more PD patients.

ACKNOWLEDGEMENTS
We are grateful to all the patients and the medical staff of the Neurological Rehabilitation Center of Beijing Rehabilitation Hospital who contributed to this project.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1002/brb3.2579

ORCID
Boyan Fang https://orcid.org/0000-0002-9935-433X

REFERENCES
Abbruzzese, G., Marchese, R., Avanzino, L., & Pelosin, E. (2016). Rehabilitation for Parkinson’s disease: Current outlook and future challenges. Parkinsonism & Related Disorders, 22(Suppl 1), S60–S64.

Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and Treatment of Parkinson Disease. JAMA, 323(6), 548. https://doi.org/10.1001/jama.2019.22360

Ashkan, K., Rogers, P., Bergman, H., & Ughratdar, I. (2017). Insights into the mechanisms of deep brain stimulation. Nature Reviews Neurology, 13(9), 548–554. https://doi.org/10.1038/nrneurol.2017.105

Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284–2303. https://doi.org/10.1016/s0140-6736(21)00218-x

Brown, R. G., Dittner, A., Findley, L., & Wessely, S. C. (2005). The Parkinson fatigue scale. Parkinsonism & Related Disorders, 11(1), 49–55.

Carod-Artal, F. J., Vargas, A. P., & Martinez-Martin, P. (2007).Determinants of quality of life in Brazilian patients with Parkinson’s disease. Movement Disorders, 22(10), 1408–1415. https://doi.org/10.1002/mds.20408

Chen, K. K., Jin, Z. H., Gao, L., Qi, L., Zhen, Q.-X., Liu, C., Wang, P., Liu, Y.-H., Wang, R.-D., Liu, Y.-J., Fang, J.-P., Su, Y., Yan, X.-Y., Liu, A.-X., & Fang, B.-Y. (2021). Efficacy of short-term multidisciplinary intensive rehabilitation in patients with different Parkinson’s disease motor subtypes: A prospective pilot study with 3-month follow-up. Neural Regeneration Research, 16(7), 1336–1343.

Clarke, C. E., Patel, S., Ives, N., Rick, C. E., Dowling, F., Woolley, R., Wheatley, K., Walker, M. F., & Sackley, C. M. (2016). Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology, 73(3), 291–299. https://doi.org/10.1001/jamaneurol.2015.4452

Daniels, C., Krack, P., Volkman, J., Raethjen, J., Pinsker, M. Q., Kloss, M., Tronnier, V., Schnitzler, A., Wojtecki, L., Bötz, K., Danek, A., Hikker, R., Sturm, V., Kupsch, A., Karner, E., Deuschl, G., & Witt, K. (2011). Is improvement in the quality of life after subthalamic nucleus stimulation in Parkinson’s disease predictable? Movement Disorders, 26(14), 2516–2521. https://doi.org/10.1002/mds.23907

D’Orio, A., Vitale, C., Piscopo, F., Baiano, C., Falanga, A. P., Longo, K., Amboni, M., Barone, P., & Santangelo, G. (2017). Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson’s disease. Parkinsonism & Related Disorders, 43, 114–117.

Frazzitta, G., Bertotti, G., Riboldazzi, G., Turla, M., Uccellini, D., Boveri, N., Guaglio, G., Perini, M., Comi, C., Balbi, P., & Maestri, R. (2012). Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: A randomized controlled trial with 1-year follow-up. Neurehabilitation and Neural Repair, 26(2), 144–150. https://doi.org/10.1177/1545968311416990

Frazzitta, G., Bertotti, G., Riboldazzi, G., Turla, M., Uccellini, D., Boveri, N., Guaglio, G., Perini, M., Comi, C., Pezzoli, G., & Ghilardi, M. F. (2015). Intensive rehabilitation treatment in early Parkinson’s disease: A randomized pilot study with a 2-year follow-up. Neurehabilitation and Neural Repair, 29(2), 123–131. https://doi.org/10.1177/1545968315442981

Goetz, C. G., Fahn, S., Martinez-Martin, P., Poewe, W., Sampaio, C., Stebbins, G. T., Stern, M. B., Tilley, B. C., Dodel, R., Dubois, B., Holloway, R., Jankovic, J., Klose, J., Lees, A., Leurgans, S., Lewitt, P. A., Nyenhuis, D., Olanow, C. W., ... Lapelle, N. (2007). Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders: Official Journal of the Movement Disorder Society, 22(1), 41–47. https://doi.org/10.1002/mds.21198

Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: onset, progression, and mortality. Neurology, 17(5), 427–427. https://doi.org/10.1212/wnl.17.5.427

Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology, 59(1), 12–19. https://doi.org/10.1037/0022-006X.59.1.12

Lamotte, G., Rafferty, M. R., Prodoehl, J., Kohrt, W. M., Comella, C. L., Simuni, T., & Corcos, D. M. (2015). Effects of endurance exercise training on the motor and non-motor features of Parkinson’s disease: A review. Journal of Parkinson’s Disease, 5(1), 21–41. https://doi.org/10.3233/JPD-140425

Liu, F. T., Lang, L. Q., Yang, Y. J., Zhao, J., Feng, R., Hu, J., Wang, J., & Wu, J.-J. (2019). Predictors to quality of life improvements after subthalamic stimulation in Parkinson’s disease. Acta Neurologica Scandinavica, 139(4), 346–352.

Martinez-Martin, P. (2017). What is quality of life and how do we measure it? Relevance to Parkinson’s disease and movement disorders. Movement Disorders, 32(3), 382–392. https://doi.org/10.1002/mds.26885

Monticone, M., Ambrosini, E., Laurini, A., Rocca, B., & Foti, C. (2015). In-patient multidisciplinary rehabilitation for Parkinson’s disease: A
randomized controlled trial. Movement Disorders, 30(8), 1050–1058. https://doi.org/10.1002/mds.26256

Montorio, I., & Izal, M. (1996). The geriatric depression scale: A review of its development and utility. International Psychogeriatrics, 8(1), 103–112. https://doi.org/10.1017/S1041610296002505

Morris, M. E., Iansek, R., & Kirkwood, B. (2009). A randomized controlled trial of movement strategies with exercise compared with people with Parkinson’s disease. Movement Disorders, 24(1), 64–71. https://doi.org/10.1002/mds.22295

Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x

Neff, C., Wang, M. C., & Martel, H. (2018). Using the PDQ-39 in routine care for Parkinson’s disease. Parkinsonism & Related Disorders, 53, 105–107.

Oguh, O., Eisenstein, A., Kwasny, M., & Simuni, T. (2014). Back to the basics: Regular exercise matters in parkinson’s disease: Results from the National Parkinson Foundation QII registry study. Parkinsonism & Related Disorders, 20(11), 1221–1225.

Playford, E. D. (2003). Multidisciplinary rehabilitation for people with Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 74(2), 148–149. https://doi.org/10.1136/jnnp.74.2.148

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders, 30(12), 1591–1601. https://doi.org/10.1002/mds.26424

Rafferty, M. R., Schmidt, P. N., Luo, S. T., Li, K., Marras, C., Davis, T. L., Guttmann, M., Cubillos, F., & Simuni, T. (2017). Regular exercise, quality of life, and mobility in Parkinson’s disease: A longitudinal analysis of national parkinson foundation quality improvement initiative data. Journal of Parkinson’s Disease, 7(1), 193–202. https://doi.org/10.3233/JPD-160912

Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in Parkinson’s disease: The relative importance of the symptoms. Movement Disorders: Official Journal of the Movement Disorder Society, 23(10), 1428–1434. https://doi.org/10.1002/mds.21667

Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in Parkinson’s disease: The relative importance of the symptoms. Movement Disorders, 23(10), 1428–1434. https://doi.org/10.1002/mds.21667

Ritter, V. C., & Bonsaksen, T. (2019). Improvement in quality of life following a multidisciplinary rehabilitation program for patients with Parkinson’s disease. Journal of Multidisciplinary Healthcare, 12, 219–227. https://doi.org/10.2147/JMDH.S202827

Rodrígues De Paula, F., Teixeira-Salmela, L. F., Coelho De Morais Faria, C. D., Rocha De Brito, P., & Cardoso, F. (2006). Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson’s disease. Movement Disorders, 21(8), 1073–1077. https://doi.org/10.1002/mds.20763

Schrag, A., Siddiqui, U. F., Anastasiou, Z., Weintraub, D., & Schott, J. M. (2017). Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: A cohort study. The Lancet Neurology, 16(1), 66–75. https://doi.org/10.1016/S1474-4422(16)30328-3

Schuepbach, W. M. M., Tonder, L., Schnitzler, A., Krack, P., Rau, J., Hartmann, A., Hälig, T. D., Pineau, F., Falk, A., Paschen, L., Paschen, S., Volkman, J., Dafarsi, H. S., Barbe, M. T., Fink, G. R., Kühn, A., Kupsch, A., Schneider, G.- H., Seigneuret, E., … Deuschl, G. (2019). Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology, 92(10), e1109–e1120. https://doi.org/10.1212/WNL.0000000000007037

Starkstein, S., Mayberg, H., Prestioli, T., Andrezejewski, P., Leiguarda, R., & Robinson, R. (1992). Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 4(2), 134–139.

Tang, Y., Liang, X., Han, L., Peng, F., Shen, B. O., Yu, H., Shen, Y., Shen, C., Yu, J., & Wang, J. (2020). Cognitive function and quality of life in Parkinson’s disease: A cross-sectional study. Journal of Parkinson’s Disease, 10(3), 1209–1216. https://doi.org/10.3233/JPD-202097

Tickle-Degnen, L., Ellis, T., Saint-Hilaire, M. H., Thomas, C. A., & Wagenaar, R. C. (2010). Self-management rehabilitation and health-related quality of life in Parkinson’s disease: A randomized controlled trial. Movement Disorders, 25(2), 194–204. https://doi.org/10.1002/mds.22940

Wade, D. T., Gage, H., Owen, C., Trend, P., Grossmith, C., & Kaye, J. (2003). Multidisciplinary rehabilitation for people with Parkinson’s disease: A randomised controlled study. Journal of Neurology, Neurosurgery, and Psychiatry, 74(2), 158–162. https://doi.org/10.1136/jnnp.74.2.158

Witt, K., Daniels, C., Krack, P., Volkmann, J., Pinsker, M. O., Kloss, M., Tronnier, V., Schnitzler, A., Wojteczek, L., Bötzel, K., Danek, A., Hilker, R., Sturm, V., Kupsch, A., Karner, E., & Deuschl, G. (2011). Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson’s disease. Journal of the Neurological Sciences, 310(1-2), 261–266. https://doi.org/10.1016/j.jns.2011.06.028

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Meng, D., Jin, Z., Chen, K., Yu, X., Wang, Y., Du, W., Wei, J., Xi, J., & Fang, B. (2022). Quality of life predicts rehabilitation prognosis in Parkinson’s disease patients. Brain and Behavior, 12, e2579. https://doi.org/10.1002/brb3.2579